3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Breast Neoplasms
145
Neoplasm Metastasis
16
Advanced Breast Cancer
9
Neoplasms
8
Ovarian Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Breast Cancer Metastatic
5
Prostatic Neoplasms
4
Endometrial Neoplasms
4
Recurrence
3
Hereditary Sensory and Autonomic Neuropathies
3
Lung Neoplasms
2
Hyperglycemia
2
Exanthema
2
Estrogen Receptor-positive Breast Cancer
2
Colorectal Neoplasms
2
Carcinoma, Lobular
2
Breast Neoplasms, Male
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Endometrial Stromal
1
Salivary Gland Neoplasms
1
Recurrent Uterine Corpus Carcinoma
1
Neoplastic Cells, Circulating
1
Interventions
Ipilimumab
106
Nivolumab
101
pembrolizumab
90
aldesleukin
72
Cyclophosphamide
46
Interleukin-2
45
Temozolomide
36
Dacarbazine
32
trametinib
31
dabrafenib
30
fludarabine phosphate
29
incomplete Freund's adjuvant
27
Bevacizumab
26
sargramostim
25
Vemurafenib
25
fludarabine
22
binimetinib
21
Radiosurgery
21
Paclitaxel
20
encorafenib
19
Carboplatin
19
CTLA-4 Antigen
18
cobimetinib
16
atezolizumab
15
Radiotherapy
14
Biopsy
14
Sorafenib
13
MART-1 Antigen
12
talimogene laherparepvec
11
montanide ISA 51
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Melanoma
×
Fulvestrant
×
Clear all
NCT07340619
2026-05-19
EPIBREAST
UNICANCER
Phase 2
Not yet recruiting
51 enrolled